FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody or an antigen-binding fragment thereof, which specifically bind to human CD127, as well as a composition and a kit containing it. Also disclosed is a combination of isolated nucleic acid molecules coding said antibody or antigen-binding fragment thereof.
EFFECT: invention is effective for treating a condition relieved or prevented by antagonizing IL7-R signaling induced by IL7.
29 cl, 11 dwg, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
